These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16156685)

  • 1. Anticoagulant use in patients with chronic renal impairment.
    Grand'Maison A; Charest AF; Geerts WH
    Am J Cardiovasc Drugs; 2005; 5(5):291-305. PubMed ID: 16156685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation in children: Making the most of little patients and little evidence.
    Young G; Male C; van Ommen CH
    Blood Cells Mol Dis; 2017 Sep; 67():48-53. PubMed ID: 28552476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia.
    Guzzi LM; McCollum DA; Hursting MJ
    J Thromb Thrombolysis; 2006 Dec; 22(3):169-76. PubMed ID: 17103051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Hirsh J; Bauer KA; Donati MB; Gould M; Samama MM; Weitz JI
    Chest; 2008 Jun; 133(6 Suppl):141S-159S. PubMed ID: 18574264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin and other rapidly acting anticoagulants.
    Hyers TM
    Semin Vasc Surg; 2005 Sep; 18(3):130-3. PubMed ID: 16168887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulants in children and adolescents.
    Young G
    Hematology Am Soc Hematol Educ Program; 2015; 2015():111-6. PubMed ID: 26637709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.
    Eriksson UG; Johansson S; Attman PO; Mulec H; Frison L; Fager G; Samuelsson O
    Clin Pharmacokinet; 2003; 42(8):743-53. PubMed ID: 12846595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond unfractionated heparin and warfarin: current and future advances.
    Hirsh J; O'Donnell M; Eikelboom JW
    Circulation; 2007 Jul; 116(5):552-60. PubMed ID: 17664384
    [No Abstract]   [Full Text] [Related]  

  • 9. Old and new antithrombotic drugs in neonates and infants.
    Young G
    Semin Fetal Neonatal Med; 2011 Dec; 16(6):349-54. PubMed ID: 21816695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in parenteral anticoagulation for arterial and venous thromboembolism.
    van Es N; Bleker SM; Büller HR; Coppens M
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):203-13. PubMed ID: 23953908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged half-life of argatroban in patients with renal dysfunction and antiphospholipid antibody syndrome being treated for heparin-induced thrombocytopenia.
    Athar U; Husain J; Hudson J; Lynch J; Gajra A
    Am J Hematol; 2008 Mar; 83(3):245-6. PubMed ID: 17910040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of ximelagatran.
    Wolzt M; Sarich TS; Eriksson UG
    Semin Vasc Med; 2005 Aug; 5(3):245-53. PubMed ID: 16123911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender.
    Robson R; White H; Aylward P; Frampton C
    Clin Pharmacol Ther; 2002 Jun; 71(6):433-9. PubMed ID: 12087346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of newer anticoagulants in patients with chronic kidney disease.
    Lobo BL
    Am J Health Syst Pharm; 2007 Oct; 64(19):2017-26. PubMed ID: 17893411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin-Induced Thrombocytopenia: A Comprehensive Clinical Review.
    Salter BS; Weiner MM; Trinh MA; Heller J; Evans AS; Adams DH; Fischer GW
    J Am Coll Cardiol; 2016 May; 67(21):2519-32. PubMed ID: 27230048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation in patients with impaired renal function and with haemodialysis. Anticoagulant effects, efficacy, safety, therapeutic options.
    Harenberg J; Hentschel VA; Du S; Zolfaghari S; Krämer R; Weiss C; Krämer BK; Wehling M
    Hamostaseologie; 2015; 35(1):77-83. PubMed ID: 25405246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients.
    Yee DL; O'Brien SH; Young G
    Clin Pharmacokinet; 2013 Nov; 52(11):967-80. PubMed ID: 23797535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin?
    Seybert AL; Coons JC; Zerumsky K
    Pharmacotherapy; 2006 Feb; 26(2):229-41. PubMed ID: 16466327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
    Ufer M
    Clin Pharmacokinet; 2005; 44(12):1227-46. PubMed ID: 16372822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.